NASDAQ : IMVT
Immunovant, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 29.64 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 6.12B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 67.91M | 76.24M | 77.23M | 57.28M | 48.02M | 54.23M |
| Research & Development | 498.09M | 456.66M | 360.92M | 212.93M | 160.26M | 101.81M |
| Operating Expenses | 566.00M | 532.90M | 438.15M | 270.21M | 208.28M | 156.03M |
| Operating Income | -566.00M | -532.90M | -438.15M | -270.21M | -208.28M | -156.03M |
| Interest & Investment Income | 26.09M | 25.33M | 24.73M | 24.95M | 7.58M | |
| Other Non Operating Income (Expenses) | 998.00K | 2.18M | 471.00K | -1.01M | -253.00K | -781.00K |
| EBT Excluding Unusual Items | -538.91M | -505.39M | -412.95M | -246.27M | -200.95M | -156.81M |
| Pretax Income | -538.91M | -505.39M | -412.95M | -258.77M | -210.95M | -156.81M |
| Income Tax Expense | -698.00K | 215.00K | 891.00K | 567.00K | 9.00K | -84.00K |
| Net Income | -538.22M | -505.61M | -413.84M | -259.34M | -210.96M | -156.73M |
| Net Income to Common | -538.22M | -505.61M | -413.84M | -259.34M | -210.96M | -156.73M |
| Shares Outstanding (Basic) | 191.09M | 182.42M | 151.57M | 138.10M | 123.08M | 109.68M |
| Shares Outstanding (Diluted) | 191.09M | 182.42M | 151.57M | 138.10M | 123.08M | 109.68M |
| EPS (Basic) | -2.82 | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 |
| EPS (Diluted) | -2.82 | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 |
| Free Cash Flow | -414.31M | -407.32M | -376.63M | -214.59M | -188.39M | -106.37M |
| Free Cash Flow Per Share | -2.17 | -2.23 | -2.48 | -1.55 | -1.53 | -0.97 |
| EBITDA | -565.61M | -532.49M | -437.77M | -269.98M | -208.08M | -155.91M |
| D&A For EBITDA | 394.00K | 409.00K | 377.00K | 231.00K | 193.00K | 126.00K |
| EBIT | -566.00M | -532.90M | -438.15M | -270.21M | -208.28M | -156.03M |
Balance sheet
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 797.80M | 902.11M | 713.97M | 635.37M | 376.53M | 493.82M |
| Cash & Short-Term Investments | 797.80M | 902.11M | 713.97M | 635.37M | 376.53M | 493.82M |
| Accounts Receivable | 700.00K | 12.23M | ||||
| Other Receivables | 697.00K | 3.95M | 2.51M | 5.50M | 185.00K | 632.00K |
| Receivables | 697.00K | 3.95M | 2.51M | 5.50M | 885.00K | 12.86M |
| Prepaid Expenses | 52.68M | 42.76M | 51.18M | 24.90M | 26.92M | 6.25M |
| Total Current Assets | 851.18M | 948.82M | 767.66M | 665.77M | 404.33M | 512.93M |
| Property, Plant & Equipment | 351.00K | 515.00K | 942.00K | 595.00K | 1.50M | 2.63M |
| Other Long-Term Assets | 961.00K | 7.68M | 7.62M | |||
| Total Assets | 852.49M | 957.01M | 776.22M | 666.37M | 405.84M | 515.56M |
| Accounts Payable | 10.14M | 7.54M | 17.66M | 7.16M | 1.35M | 18.63M |
| Accrued Expenses | 64.48M | 96.63M | 50.75M | 41.30M | 40.42M | 24.57M |
| Current Portion of Leases | 72.00K | 98.00K | 138.00K | 1.17M | 1.15M | |
| Other Current Liabilities | 42.48M | 175.00K | 273.00K | 15.00K | 350.00K | 171.00K |
| Total Current Liabilities | 117.10M | 104.42M | 68.78M | 48.61M | 43.30M | 44.52M |
| Long-Term Leases | 47.00K | 1.22M | ||||
| Total Liabilities | 117.10M | 104.42M | 68.78M | 48.61M | 43.34M | 45.74M |
| Common Stock | 20.00K | 20.00K | 16.00K | 14.00K | 13.00K | 12.00K |
| Additional Paid-In Capital | 2.63B | 2.60B | 1.95B | 1.44B | 927.98M | 824.80M |
| Retained Earnings | -1.90B | -1.75B | -1.24B | -825.68M | -566.35M | -355.39M |
| Comprehensive Income & Other | 725.00K | 730.00K | 1.46M | 1.91M | 852.00K | 404.00K |
| Shareholders' Equity | 735.39M | 852.59M | 707.45M | 617.76M | 362.49M | 469.82M |
| Total Liabilities & Equity | 852.49M | 957.01M | 776.22M | 666.37M | 405.84M | 515.56M |
| Total Debt | 72.00K | 98.00K | 138.00K | 1.22M | 2.36M | |
| Net Cash (Debt) | 797.80M | 902.04M | 713.87M | 635.23M | 375.31M | 491.45M |
| Net Cash Per Share | 4.17 | 4.94 | 4.71 | 4.60 | 3.05 | 4.48 |
| Filing Date Shares Outstanding | 206.55M | 205.31M | 170.92M | 146.05M | 130.41M | 116.51M |
| Total Common Shares Outstanding | 206.26M | 203.94M | 170.11M | 145.58M | 130.33M | 116.48M |
| Working Capital | 734.08M | 844.40M | 698.89M | 617.16M | 361.04M | 468.41M |
| Book Value Per Share | 3.57 | 4.18 | 4.16 | 4.24 | 2.78 | 4.03 |
| Tangible Book Value | 735.39M | 852.59M | 707.45M | 617.76M | 362.49M | 469.82M |
| Tangible Book Value Per Share | 3.57 | 4.18 | 4.16 | 4.24 | 2.78 | 4.03 |
Cash flow statement
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Net Income | -538.22M | -505.61M | -413.84M | -259.34M | -210.96M | -156.73M |
| Depreciation & Amortization | 394.00K | 409.00K | 377.00K | 231.00K | 193.00K | 126.00K |
| Stock-Based Compensation | 50.99M | 55.72M | 49.49M | 41.12M | 32.30M | 34.24M |
| Other Operating Activities | 102.00K | 99.00K | 133.00K | 1.13M | 1.13M | 1.11M |
| Change in Accounts Receivable | 1.29M | 986.00K | 3.23M | -4.58M | 11.76M | -11.63M |
| Change in Accounts Payable | 1.75M | -10.25M | 10.68M | 5.78M | -17.12M | 16.25M |
| Change in Income Taxes | -2.39M | -2.39M | -261.00K | 19.00K | 461.00K | -85.00K |
| Change in Other Net Operating Assets | 71.78M | 53.72M | -25.69M | 1.41M | -5.95M | 10.61M |
| Operating Cash Flow | -414.30M | -407.31M | -375.87M | -214.23M | -188.19M | -106.11M |
| Capital Expenditures | -8.00K | -8.00K | -759.00K | -360.00K | -197.00K | -254.00K |
| Investing Cash Flow | -8.00K | -8.00K | -759.00K | -360.00K | -197.00K | -254.00K |
| Issuance of Common Stock | 613.44M | 596.26M | 454.81M | 478.44M | 71.16M | 200.13M |
| Other Financing Activities | -504.00K | -504.00K | -319.00K | -6.01M | -272.00K | |
| Financing Cash Flow | 612.93M | 595.76M | 454.49M | 472.43M | 70.89M | 200.13M |
| Foreign Exchange Rate Adjustments | 263.00K | -299.00K | 747.00K | 993.00K | 220.00K | -92.00K |
| Net Cash Flow | 198.89M | 188.14M | 78.61M | 258.83M | -117.28M | 93.67M |
| Free Cash Flow | -414.31M | -407.32M | -376.63M | -214.59M | -188.39M | -106.37M |
| Free Cash Flow Per Share | -2.17 | -2.23 | -2.48 | -1.55 | -1.53 | -0.97 |
| Levered Free Cash Flow | -238.70M | -234.28M | -227.82M | -124.15M | -107.82M | -47.88M |
| Unlevered Free Cash Flow | -238.70M | -234.28M | -227.82M | -124.15M | -107.82M | -47.88M |
| Cash Income Tax Paid | 2.39M | 2.39M | 1.20M | 509.00K | ||
| Change in Working Capital | 72.43M | 42.06M | -12.03M | 2.63M | -10.85M | 15.14M |
Ratios
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 6.03B | 5.06B | 2.90B | 4.69B | 2.00B | 641.34M |
| Enterprise Value | 5.23B | 4.06B | 2.53B | 4.00B | 1.57B | 117.10M |
| Last Close Price | 29.17 | 24.84 | 17.09 | 32.31 | 15.51 | 5.51 |
| PB Ratio | 8.18 | 5.93 | 4.10 | 7.60 | 5.53 | 1.36 |
| P/TBV Ratio | 8.19 | 5.93 | 4.10 | 7.60 | 5.53 | 1.36 |
| Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | |
| Net Debt / Equity Ratio | -1.08 | -1.06 | -1.01 | -1.03 | -1.03 | -1.05 |
| Net Debt / EBITDA Ratio | 1.41 | 1.69 | 1.63 | 2.35 | 1.80 | 3.15 |
| Net Debt / FCF Ratio | 1.93 | 2.21 | 1.90 | 2.96 | 1.99 | 4.62 |
| Quick Ratio | 6.82 | 8.68 | 10.42 | 13.18 | 8.72 | 11.38 |
| Current Ratio | 7.27 | 9.09 | 11.16 | 13.70 | 9.34 | 11.52 |
| Return on Equity (ROE) | -80.10% | -64.82% | -62.46% | -52.91% | -50.69% | -36.39% |
| Return on Assets (ROA) | -46.73% | -38.43% | -37.97% | -31.50% | -28.26% | -21.02% |
| Return on Capital Employed (ROCE) | -77.00% | -62.50% | -61.90% | -43.70% | -57.40% | -33.10% |
| Earnings Yield | -9.66% | -10.00% | -14.26% | -5.52% | -10.52% | -24.44% |
| FCF Yield | -6.88% | -8.06% | -12.97% | -4.57% | -9.40% | -16.59% |
| Buyback Yield / Dilution | -21.12% | -20.35% | -9.76% | -12.21% | -12.21% | -24.98% |